DFM Funding Monitor

PANDEMIC PREPAREDNESS THROUGH INTRANASAL ADMINISTRATION OF BROADLY EFFECTIVE MONOCLONAL ANTIBODIES AGAINST ALL INFLUENZA STRAINSbroad

PanFlu · Horizon Europe grant · 2025-11-01–2027-10-31

EC contribution

€2,499,999

Total cost

€0

Beneficiaries

1

About the data

Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2024-ACCELERATOR-02 · scheme HORIZON-EIC-ACC · topic HORIZON-EIC-2024-ACCELERATORCHALLENGES-05. CORDIS record →

Objective

Respiratory infectious diseases pose a significant threat to global health, spreading rapidly and hindering containment. The COVID-19 pandemic, with over 450 million cases in two years, highlighted the need for effective preventive measures beyond vaccines and antivirals, which have notable limitations.Leyden Labs is pioneering a groundbreaking platform to counter evolving viral threats with nasal sprays developed using the world's most broadly neutralizing anti-influenza antibody (name disclosed in the short proposal). Our technology features high-affinity binding antibodies targeting the virus to prevent immune escape, with intranasal delivery ensuring targeted protection at the infection site for enhanced efficacy and convenience.Our primary market is EU healthcare providers, working closely with EU health authorities for effective pandemic response. Success in the EU will pave the way for global expansion, including the US market. Our nasal sprays will be available by prescription and through government partnerships, with revenue from insurance coverage and government contracts.This innovative platform aims to significantly improve pandemic preparedness and global health security. EU funding is crucial for financial support and strategic collaborations with EU healthcare providers, positioning us as leaders in healthcare innovation. The 2024 EIC Accelerator challenge will support the development of broad-spectrum monoclonal antibody-based therapeutics, ensuring efficacy against resistant variants.

Beneficiaries (1)

Organisation	Country	Role	EC contribution	SME
LEYDEN LABORATORIES BV	NL	coordinator	€2,499,999	Yes

Get the DFM funding briefing — free

New EU defence calls, tenders and awards in your inbox.

Countries

Germany France Poland Spain Italy

Sectors

Security equipment Military vehicles Weapons & ammunition Military aircraft Warships & naval Military electronics

Sources

calls tenders awards research

I agree to receive the DFM Analysis briefing and funding alerts by email. I can unsubscribe at any time.

Website

Subscribe free

We store your email only to send the DFM briefing/alerts and to add you to DFM Analysis. Unsubscribe anytime.

Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.